Encouraging results for an incurable bone cancer
Does tumor location matter?
An IL-15 superagonist shows promise
New adjuvant therapies, advances in neoadjuvant
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Men with the HSD3B1(1245C) variant metabolize abiraterone differently
Planning avoids surprises, improves outcomes
Why it should be considered more often
Favorites chosen by Cleveland Clinic’s solid tumor staff
Cleveland Clinic's approach to the therapy
13-year retrospective shows evolution of treatment for aggressive disease
Advertisement
Advertisement